What question did this study set out to answer?

To identify the pathophysiological mechanism responsible for acquired platelet dysfunction and bleeding symptoms in a patient presenting with chronic myeloid leukaemia and thrombocytosis.

July 1, 1982British Journal of Haematology

Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia

View Full Paper

Ask AI

Bookmark

Population

A patient with chronic myeloid leukaemia presenting with petechiae and thrombocytosis (n=1)

Design

Case_report

Authors

MOMinoru OkumaKyoto University HTHiroshi TakayamaShinshu University HUHaruto UchinoHokkaido University

Discussion

Member takes

Implication

May explain bleeding in CML thrombocytosis; hypothesis-generating for TXA2 unresponsiveness and requires confirmation in larger cohorts.

Key Points

To identify the pathophysiological mechanism responsible for acquired platelet dysfunction and bleeding symptoms in a patient presenting with chronic myeloid leukaemia and thrombocytosis.
Assessed platelet aggregation and ATP release in platelet-rich plasma from a single patient (N=1) using agonists such as arachidonic acid, collagen, A23187, ADP, epinephrine, and ristocetin.
Measured platelet 14C-serotonin uptake, adenine nucleotide levels, and arachidonic acid metabolism via thin-layer radiochromatography.
Tested platelet responsiveness to exogenous thromboxane A2 and evaluated the aggregating potency of patient-generated thromboxane A2 on control platelets.
Platelet aggregation in response to arachidonic acid, collagen, and A23187 was decreased, with absent ATP release and defective secondary aggregation to ADP and epinephrine.
Arachidonic acid metabolism and the aggregating capacity of patient-derived thromboxane A2 were fully preserved.
Patient platelets exhibited only minimal, reversible aggregation upon exposure to thromboxane A2, confirming an intrinsic failure to respond to the agonist.

Structured PICO

Population

A patient with chronic myeloid leukaemia presenting with petechiae and thrombocytosis (n=1)

Intervention

In vitro platelet function testing (aggregation induced by arachidonic acid, collagen, A23187, ADP, epinephrine, ristocetin, and thromboxane A2)

Outcome

Platelet aggregation response to various agonists and thromboxane A2surrogate

Identifies a novel mechanism of acquired platelet hypofunction in a patient with chronic myeloid leukemia, characterized by a subnormal response to thromboxane A2 despite normal TXA2 production.

Cite This Study

Okuma et al. (1982) studied this question.

synapsesocial.com/papers/6a8bef6cb676b7d1a2fb87e6 https://doi.org/10.1111/j.1365-2141.1982.tb02804.x

View Full Paper

Ask AI

Bookmark

Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider